Connect with us

Insight

IVF in transition: 2025 realities and what device manufacturers must do now

Published

on

FinDBest IVF is a global B2B platform that connects manufacturers of fertility and reproductive health devices with IVF-specialist distributors in over 150 countries. We simplify global expansion, regulatory pathway planning, and distributor onboarding.

Each year, the European Society of Human Reproduction and Embryology (ESHRE) Congress reveals not just clinical updates, but also clear signals about where the IVF market is heading.

In 2025, Circular Communications compiled a focused commercial and product roadmap briefing from the event, kindly shared recently by Dr Georg Griesinger on Linkedin.

What follows is a practical breakdown of their insights—designed for medical device manufacturers and clinical users who need to make fast, evidence-based business and product decisions:

The Six Shifts Reshaping IVF

The IVF landscape in 2025 is not simply evolving—it is undergoing structural change.

Six key forces are reshaping how medical devices are adopted, evaluated, and purchased. Manufacturers who adapt early will find more predictable paths to market.

Those who do not risk falling behind as clinics tighten their criteria.

Cost pressures are now the central constraint

IVF remains financially inaccessible for large segments of the population.

In many countries, patients are still paying out of pocket.

The result is a growing preference for solutions designed around total cost of ownership (TCO).

That means not just upfront purchasing price/cost, but reusability, reliability, throughput, maintenance needs, and training time.

Products that align with capital expenditure (CAPEX) models and flexible subscriptions—especially those matched to clinic cash flow—are more likely to be adopted.

Growth in mature markets has flatlined

In many high-income countries, the number of IVF cycles per capita has plateaued.

For manufacturers, that means growth must now come from share gain or geographic expansion, particularly into fast-growing regions like Southeast Asia, the Middle East and North Africa (MENA), and Latin America.

But entering these markets successfully requires localising value propositions and working with distributors who understand IVF workflows and regulatory constraints.

Legal and ethical oversight is tightening

Questions about embryo selection, long-term storage, and artificial intelligence (AI) in diagnostics are under increased scrutiny.

For manufacturers, this raises the bar on traceability, audit readiness, and labeling compliance.

Products now need to include support for standard operating procedures (SOPs), as well as detailed logging and audit trails.

These are no longer differentiators—they are minimum requirements.

Patient experience has become a key decision factor

Clinics are under pressure to not only deliver outcomes but also reduce the emotional and cognitive burden on patients.

Devices that simplify communication, reduce the number of steps in a procedure, and help patients understand “what’s next” are increasingly favored.

Clear interfaces, intuitive indicators, and minimal user intervention all contribute to better adoption.

Clinic consolidation is shifting how buying decisions are made

Independent clinics are being replaced or absorbed by multi-site groups (Eg. US Fertility or IVIRMA, owned by KKR).

These groups prioritise enterprise-style purchasing: standardised protocols, centralised training, measurable return on investment (ROI), and clear service levels.

Manufacturers that can offer SOP kits, multi-site onboarding, and enterprise-level value metrics will have a distinct advantage.

Technology alone no longer drives differentiation

Automation, AI, microfluidics, smart incubation systems, and digital integration are becoming standard.

The key to winning adoption now lies in reproducibility, data quality, interoperability, and auditability—not just product specifications.

Clinics expect devices that integrate easily with their digital systems and produce consistent results across different settings.

Each of these shifts presents a challenge, but also a roadmap.

Cost, regulation, technology, and buyer behavior are all converging toward a more structured and evidence-driven IVF market.

Manufacturers who address these realities in their design, pricing, and commercial execution will be best positioned to scale.

Clinical and Technological Frontiers Highlighted at ESHRE 2025

Beyond the market dynamics, ESHRE 2025 spotlighted several areas of clinical innovation that are directly shaping device and diagnostics development.

These themes are not theoretical—they are influencing purchasing, adoption, and regulatory expectations now.

Ovarian stimulation protocols are being rethought As clinics aim for personalisation and patient comfort, the need for smarter diagnostics and more flexible drug delivery systems is growing.

Biomarkers that can predict ovarian reserve and treatment response are informing stimulation protocols, making room for devices that adapt to individual profiles.

At the same time, there is a clear trend toward mild stimulation protocols, which create demand for less-invasive monitoring tools and delivery systems that are intuitive, reliable, and easy to train on.

The ongoing refinement of protocols using gonadotropin-releasing hormone (GnRH) antagonists reinforces the need for workflow-agnostic solutions—those that can fit into varying cycles without adding complexity.

Embryo selection is moving well beyond morphology

Objective, evidence-backed methods are replacing subjective scoring.

One major area of interest is AI-supported time-lapse imaging, which offers the potential to assess embryo viability in a more standardised and reproducible way.

However, clinics are demanding validated tools—classified appropriately as software as a medical device (SaMD), with integration capabilities and clean clinical evidence.

In parallel, non-invasive preimplantation genetic testing (niPGT) is gaining momentum.

Media capable of capturing cell-free DNA (cfDNA), paired with ultra-sensitive genetic testing platforms, could redefine embryo selection workflows.

This is not a future trend—it’s a present R&D priority.

Manufacturers need to plan both the evidence and regulatory strategy from the outset.

Metabolomics and biomarker analysis of culture media are also being explored, particularly where kits can offer clear utility and fit easily into existing lab infrastructure.

Implantation remains a key bottleneck

Even with viable embryos, successful transfer remains challenging.

There is growing interest in non-invasive endometrial diagnostics that can assess uterine receptivity without disrupting workflow.

The market demands tools that are specific, reproducible, and easy to use.

Meanwhile, catheter design continues to influence both outcomes and patient experience.

Ergonomics, atraumatic placement, and consistent delivery are still core drivers of successful transfers.

While less discussed in marketing, this area remains a top priority for clinical users and therefore deserves more innovation attention.

Taken together, these frontiers point toward a product development path that favors integration over novelty, reproducibility over experimentation, and real-world usability over theoretical performance.

It is not just what your device does—it is how it fits into the day-to-day life of clinics under pressure.

Regulatory and Market Access: Build It In, Not On

Global regulatory expectations are rising, and shortcuts are closing.

Product teams can no longer afford to treat compliance as a post-development task. It must be embedded from Day 0.

For software and AI-based tools, classification is tightening across the United States, European Union, and China.

This means developers must create full validation plans early, align endpoints with regulatory expectations, and document cybersecurity and data governance practices before launch.

Post-market surveillance and post-market clinical follow-up are not optional; they need to be built into the development process.

Culture media and reagent products are under increased scrutiny from regulations like the European Union’s Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).

Manufacturers must establish robust quality systems, ensure all labeling is complete and language-appropriate, and be ready to implement unique device identification requirements in every target market.

For connected lab devices, regulatory bodies expect more than just functionality.

They now require detailed documentation of data interoperability, security protocols, and integration capabilities.

Manufacturers should design clean application programming interfaces (APIs) and seamless connectors for hospital and laboratory data systems to make compliance easier—not harder—for clinics.

A practical checklist for manufacturers:

  • Confirm software classification and plan validation early for each market.
  • Create templates for traceability, labeling, audit logs, and PMS/PMCF.
  • Implement cybersecurity and data protection frameworks from Day 0.
  • Ensure unique device identification (UDI) compliance for each geography.
  • Offer clear integration documents for lab systems (no assumptions).

Strategic Focus Areas for IVF Device and Diagnostics Manufacturers

  • Balance cost and innovation
    Demonstrate lower total cost of ownership through real-world data. Show how your product reduces maintenance, training time, or consumable use.
  • Support with evidence, not claims
    Build prospective, multi-site clinical studies. Prepare audit-ready documentation: instructions for use, labeling, traceability, and surveillance templates.
  • Integrate digital and physical
    Provide open, secure APIs. Ensure fast and simple onboarding for embryologists and nurses. Focus on reducing clicks, errors, and delays.
  • Refine embryo selection strategy
    Align product claims with validated inputs—whether AI models, cfDNA media, or metabolomic markers. Monitor data drift and revalidate regularly.
  • Improve uterine receptivity and transfer tools
    Support claims with performance data (e.g. time to placement, consistency). Offer quick training modules to accelerate adoption.
  • Embed regulatory design
    Maintain a live matrix of requirements per SKU and market. Don’t delay planning for UDI, cybersecurity, PMS/PMCF.
  • Sell to enterprise buyers
    Offer group-level SOP kits, ROI calculators, and centralised onboarding. Provide remote diagnostics and clear SLAs to reduce downtime.
  • Speed up market entry through smarter distribution
    Use IVF-experienced distributors with proven regulatory capabilities. Shorten time to first order by removing the guesswork.

Key Takeaways

  • Total cost of ownership is now the key metric—design around it.
  • Patient workflows and clinic processes must be simplified.
  • Reproducibility and integration matter more than specs.
  • Plan evidence generation around the claims you want to make.
  • Prepare for audits with full traceability and post-market tools.
  • Offer group-ready commercial packages for multi-site chains.
  • Match each market with a localised regulatory strategy.
  • Choose distributors who understand both IVF and compliance.

FinDBest IVF: Your Partner in Global Expansion

These insights from ESHRE 2025, as compiled by Circular Communications, offer a compelling glimpse into the future of fertility treatment.

For medical device manufacturers, these trends are direct signals for where to focus R&D, innovation, and market entry efforts.

At FinDBest IVF, we specialise in helping medical device manufacturers navigate the complex global regulatory landscape.

Whether you’re developing cutting-edge AI for embryo selection, next-generation culture media, or advanced cryopreservation devices, we can help you:

  • Find regulatory-savvy distributors and license holders.
  • Identify partners who understand country-specific timelines and dossier formats.
  • Expand globally, faster — with fewer surprises.

Credits

Insight

The RESIL-Card tool launches across Europe to strengthen cardiovascular care preparedness against crises

Published

on

By Women As One

Women As One is proud to have contributed to the development of the RESIL-Card tool as an active Advisory Board member, ensuring that gender equity and the perspectives of women cardiologists were embedded from the outset.

Through strategic input on the project’s design, formal support of its EU4Health funding application, and ongoing participation in advisory activities, Women As One has helped shape both the direction and implementation of this initiative.

By amplifying awareness, facilitating engagement from our global community, and advocating for inclusive representation, we have worked to ensure that RESIL-Card reflects the diverse realities of cardiovascular care and supports more equitable, resilient health systems in times of crisis. Read more about our involvement here.

On the European Day for Prevention of Cardiovascular Risk (March 14), the RESIL-Card consortium proudly announces the official launch of the RESIL-Card tool, a free online resource designed to help hospital cardiovascular professionals and other stakeholders assess and strengthen the resilience of their care pathways — ensuring that lifesaving care remains accessible even during times of crisis.

Available now at https://www.wecareabouthearts.org/resil-card/online-tool/, the RESIL-Card tool offers a structured self-assessment framework for evaluating the preparedness of cardiovascular services and identifying concrete actions to maintain continuity of care when health systems face disruption.

“Cardiovascular care must remain uninterrupted regardless of the challenges health systems face,” said Professor William Wijns, Research Professor in Interventional Cardiology, University of Galway, Ireland, and We CARE – RESIL-Card Coordinator.

“The RESIL-Card tool provides healthcare teams with a practical way to assess preparedness, identify improvement opportunities, and ultimately ensure that patients continue to receive lifesaving care when it matters most.”

Why the RESIL-Card tool was developed

Cardiovascular diseases remain the leading cause of death in Europe, making the continuity and resilience of care pathways a public health priority.

Despite advances in diagnosis and treatment, recent crises – from pandemics to geopolitical instability – have exposed the vulnerability of healthcare systems.

In today’s increasingly uncertain health landscape and global environment, proactive preparedness is no longer optional – it is essential.

The RESIL-Card tool was developed as part of an EU4Health-funded initiative to support organisations providing lifesaving cardiovascular care in strengthening their preparedness, improving coordination, and safeguarding patient outcomes in times of disruption.

The initiative focuses on practical resilience strategies to help health systems anticipate challenges rather than simply react to them.

“Healthcare systems today operate in an increasingly complex and unpredictable environment,” said Ariadna Sanz, Health Policy Manager at the Catalan Health Service (CatSalut).

“Tools like RESIL-Card help shift the focus from responding to crises toward proactively building strong, adaptable cardiovascular care pathways that protect patients over the long term.”

A collaborative and evidence-based methodology

The RESIL-Card tool is grounded in a robust, multidisciplinary development process involving cardiovascular experts, healthcare professionals, public health specialists, patient organisations, and policy stakeholders from across Europe.

Its development combined comprehensive literature reviews and analysis of existing preparedness frameworks with extensive stakeholder consultations and co-creation workshops. Real-world insights from healthcare providers and patient representatives were integrated throughout the process to ensure the tool reflects the practical realities of cardiovascular care delivery. The methodology also included iterative testing and validation phases, allowing the consortium to refine the tool and ensure it is both scientifically rigorous and practical for everyday use.

“From the outset, RESIL-Card was co-created with clinicians, patient representatives, and health system experts to ensure it reflects real-world practice,” said Professor Niek Klazinga, Em. Professor of Social Medicine, Amsterdam University Medical Centre / University of Amsterdam.

“The result is a tool that combines scientific rigour with practical usability, enabling healthcare teams to translate resilience concepts into concrete action.”

What the RESIL-Card tool is and how it works

The RESIL-Card tool is a practical online self-assessment instrument designed for use by a multistakeholder resilience team led by cardiovascular care providers.

Through a structured four-step process, including a questionnaire and guided analysis, users assess the preparedness and resilience of their cardiovascular care pathways and gain a clear understanding of how well their services can maintain care continuity during periods of disruption.

The assessment process helps teams identify existing strengths as well as potential gaps in service delivery.

Based on the responses provided, the tool offers tailored recommendations and examples of best practices to support improvement.

These insights can then inform strategic planning, helping organisations prioritise actions that reinforce care continuity, strengthen patient safety, and optimise the long-term sustainability of cardiovascular services.

Benefits for Key Stakeholders

For healthcare professionals and organisations delivering cardiovascular care, the RESIL-Card tool provides a structured way to strengthen preparedness and crisis-response capacity.

By helping teams assess their existing systems and identify areas for improvement, the tool supports better coordination across services and clinical disciplines.

It also facilitates evidence-based planning and quality improvement initiatives, enabling healthcare organisations to enhance their operational resilience while maintaining efficient and manageable care processes.

“By promoting awareness about strengths and limitations of each system, the RESIL-Card tool will help physicians to understand where improvements are needed and strengthen coordination and planning to face crises,” said Doctor Alfredo Marchese, Chief of Interventional Cardiology Department at Santa Maria Hospital, Bari, Italy and President of the Italian Society of Interventional Cardiology (GISE).

For patients and patient organisations, the RESIL-Card tool contributes to improving the reliability and continuity of essential cardiovascular care.

By encouraging healthcare providers to proactively address vulnerabilities in care pathways, the tool helps promote uninterrupted access to diagnosis, treatment, and follow-up services.

It also supports a more patient-centred and equitable approach to care delivery, encouraging collaboration and transparency in preparedness planning.

Ultimately, these improvements can contribute to better health outcomes and increased safety for people living with cardiovascular disease.

“For people living with cardiovascular disease, continuity of care is not optional — it is essential,” said Teresa Glynn, Senior Executive Strategy & Partnerships at Global Heart Hub.

“By helping healthcare providers strengthen preparedness, RESIL-Card supports more reliable and equitable access to treatment and greater confidence for patients and their families.”

At the European level, the RESIL-Card initiative contributes to a shared effort to strengthen the resilience of health systems.

By providing a common framework for assessing and improving preparedness, the tool encourages cross-border learning and facilitates the exchange of best practices among healthcare providers and policymakers.

It also aligns closely with European Union priorities on health system preparedness, crisis response, and sustainability.

By helping healthcare organisations identify vulnerabilities and implement practical resilience measures, the RESIL-Card tool can support efforts to reduce inequalities in access to high-quality cardiovascular care across EU Member States.

“Strengthening the resilience of cardiovascular care is a shared European priority,” said Rachel Kenna, Ireland’s Chief Nursing Officer at the Department of Health.

“While the RESIL-Card tool has not yet been tested in an Irish setting we look forward to seeing how it can support the development of more sustainable and prepared healthcare systems.”

Call to Action

Cardiovascular care providers and other healthcare professionals are encouraged to explore the RESIL-Card tool at https://www.wecareabouthearts.org/resil-card/online-tool/.

By using it to assess their cardiovascular care pathways, they will identify areas where resilience can be strengthened and ensure that essential services remain accessible during times of disruption.

Patient organisations also play an important role in this effort. By engaging with healthcare providers and policymakers, they can help promote the use of the tool and ensure that patient perspectives are meaningfully incorporated into preparedness and response planning.

Policymakers and health authorities are invited to support the adoption of the RESIL-Card tool within regional, national and European strategies aimed at strengthening healthcare system resilience.

Integrating the tool into policy frameworks can help safeguard access to essential cardiovascular services and enhance the ability of health systems to respond effectively to future challenges.

Learn more about Women As One at womenasone.org

Continue Reading

News

Why advocacy-orientated CPD matters for the future of cardiology

Published

on

By Women As One

At the 2026 Alliance Annual Conference, Women As One presented a poster that asked a powerful question: What if continuing professional development (CPD) did more than teach clinical knowledge— and instead helped shape the future of the workforce itself?

For decades, professional education in medicine has focused primarily on what clinicians know and how they practice. That work remains essential.

But persistent gender gaps across cardiology—from leadership positions to research participation and speaking opportunities—demonstrate that knowledge alone is not enough to ensure equitable advancement.

To truly strengthen the field of cardiology, professional development must also support who clinicians become, the opportunities they access, and the voices that shape the future of cardiovascular medicine.

Our poster, More Than Education: Elevating Equity and Identity Through CPD, explores how a new model of advocacy-orientated CPD can help close these gaps.

Advocacy-orientated CPD expands the traditional model of professional education. In addition to building clinical expertise, it intentionally supports the structural elements that shape career advancement—mentorship, sponsorship, leadership development, visibility, and professional networks.

By integrating these elements into professional education, CPD can become a powerful engine for advancing equity—and ultimately improving patient care.

Why this matters

Gender inequities in medicine are not simply workforce issues. They influence research priorities, clinical trial representation, leadership decision-making, and ultimately the care patients receive.

When women clinicians have equitable opportunities to lead, research, and shape clinical practice, the entire healthcare system benefits.

Yet structural barriers remain. Women physicians often have less access to mentorship, sponsorship networks, and leadership pathways—factors that are critical for career advancement.

This is where advocacy-orientated CPD comes in.

By intentionally designing programs that foster mentorship, build leadership skills, create visibility, and support long-term professional growth, organizations can help ensure that the next generation of cardiovascular leaders reflects the diversity of the patients they serve.

Turning opportunity into impact

Since its founding, Women As One has supported thousands of women cardiologists across more than 100 countries, expanding access to mentorship, research opportunities, and leadership development.

Through programs like CLIMB, RISE, Mentorship Awards, and our global digital community, The Pulse, thousands of women cardiologists have gained mentorship, leadership training, and opportunities that accelerate their careers and expand their influence.

Today, the outcomes of these programs are shaping the field in tangible ways:

  • Women As One alumnae are leading clinical trials and advancing cardiovascular research
  • Clinicians supported through our programs are building registries, launching new care models, and expanding access to specialized care
  • Women cardiologists are gaining greater representation on speaker panels, advisory boards, and leadership pathways
  • A global community of more than 3,000 women cardiologists is strengthening collaboration, mentorship, and visibility across the profession

These outcomes demonstrate what becomes possible when professional development goes beyond traditional education to intentionally support leadership, identity, and community.

A call to the cardiovascular community

Advancing equity in cardiology is not the responsibility of one organization—it requires a collective effort across the entire ecosystem of clinicians, educators, institutions, and industry partners.

For women cardiologists, this means engaging in the programs, mentorship networks, and leadership opportunities that help shape the future of the field. Whether through CLIMB, RISE, research initiatives, or participation in The Pulse community, your involvement strengthens a growing movement dedicated to advancing women in cardiology.

For our partners and supporters, this work demonstrates the powerful impact that strategic investment in equity-focused professional development can have on the workforce and the patients we ultimately serve.

Together, we can redefine what professional development looks like in medicine—not just as a pathway for learning, but as a catalyst for leadership, opportunity, and lasting change.

Explore the poster

We invite you to explore the poster below (click here to download it) to learn more about the evidence, framework, and real-world impact behind this work—and to join us in continuing to expand what professional development can achieve for the future of cardiovascular medicine.

Learn more about Women As One at womenasone.org

Continue Reading

Mental health

Finding each other: Peer recognition as a clinical intervention in chronic illness

Published

on

By Morgan Rose, chief science officer, Ema and Erlyn Macarayan, PhD, vice president, data science at PatientsLikeMe

May is Mental Health Awareness Month.

Most of the conversation this month treats depression and anxiety as standalone conditions, things people experience independently of their physical health.

For the patients we serve through the PLM platform, that framing leaves out something important.

Mental health in chronic illness functions as an overlay on a condition that does not end. It runs alongside the disease for as long as the disease lasts.

We have been analysing anonymised, aggregated conversational data from Ema, our agentic AI for patient support, and PLM users.

One pattern stands out across the dataset: what people are reaching for when they reach out.

The single most common behavior in the data, appearing in nearly 500 unique conversations, is the search for someone with the same diagnosis.

“Can you connect me with an MS group?” “Are there other people here with fibromyalgia?” “Does anyone in my city have what I have?” “I am looking for people like me.”

That request has a name in the research literature. It is peer support, and in the context of chronic illness, it functions as a mental health intervention.

The clinical case for peer recognition

The literature on peer support in chronic illness is well-developed.

Connection with others who share your diagnosis is associated with reduced depression severity, better treatment adherence, and a measurable drop in perceived isolation.

The mechanism behind those outcomes is recognition.

Someone else has lived inside the same symptom, navigated the same medication side effect, sat with the same diagnostic delay, and that recognition closes a specific gap that conventional therapy alone often cannot reach.

Therapists matter.

So do the people who know what an MS fatigue day actually feels like, what a fibro flare does to a person’s sense of self, what it is to be 34 and on a chemo regimen your friends cannot picture.

In clinical terms, that community is part of the care infrastructure for chronic illness, alongside medications, specialists, and labs.

PLM was built around this insight.

What Ema adds is a conversational layer that can route someone toward that community at the moment of need, before they have finished learning a platform.

“The PatientsLikeMe community has made living with MS manageable and in some bizarre way, even enjoyable sometimes because I’ve garnered these friendships and I am no longer afraid because all these other people are doing it with me.”

  • PLM member living with MS

Why the burden is hard to address inside a clinical visit

There is a structural reason the mental health weight of chronic illness routinely goes undertreated. The visit is consumed by the physical condition.

The provider’s task list is long, the slot is short, and there is rarely a person in the room whose role is to ask how the patient is actually doing.

Some of that weight is also biological.

Depression in MS, for example, is roughly twice as common as in the general population, and is frequently undiagnosed because fatigue, cognitive change, and social withdrawal can be read as MS symptoms.

Similar overlap exists across cancer, autoimmune disease, and chronic pain.

Two systems run in parallel, shaped in part by the same underlying biology, yet routinely treated as separate.

That gap is where unguarded conversation tends to appear, and where the PLM data gets revealing.

The disclosure pattern

When mental health is mentioned in the PLM dataset, it rarely appears at the start of a conversation.

It surfaces sideways, after trust has been established by a clinical or logistical question.

One thread opens with questions about gabapentin and how PatientsLikeMe works.

A few exchanges later, the same user asks whether Ema has crisis resources. The conversation moves to feeling anxious, then depressed, then “I don’t know how I feel.”

Another thread spends several turns on MS management, medication questions, and which groups exist on PLM. Then the user writes, “My MS is making me feel overwhelmed and like everything is just too much. I’m not sure how to go on.”

Ema’s response in moments like that one matters.

She receives what was actually said, validates its weight, offers concrete steps for support, and connects the user back to the PLM community for the kind of isolation a clinical encounter cannot address.

The conversation pivoted because the user needed it to, and Ema followed.

That arc, the one that begins with a logistical question and ends in a disclosure about feeling unable to go on, is one of the clearest pictures we have of what the untreated chronic illness mental health burden looks like from the inside.

Crisis in the middle of an ordinary conversation

In 25 separate conversations in the PLM dataset, the mental health weight rose to the level of crisis. Users disclosed suicidal ideation directly.

One wrote, “I’m thinking of suicide.” Another asked what to do “if having a crisis and feeling suicidal.”

These conversations were happening on a patient platform, amid otherwise routine exchanges about a chronic condition.

The disclosures came in mid-thread, with no triage process to queue them.

Ema’s response was immediate and grounded. Hotline numbers, emergency services, an acknowledgment of the seriousness, and a reminder that the person is not alone.

The infrastructure to capture a moment like that at any hour, with no wait time, is something the conventional care system struggles to provide at scale. People are reaching for something in those moments.

Ema is built to be the thing they reach toward, and to hand them off to the human resources they need next.

What the data points toward

Pulling the patterns together, a coherent picture emerges.

People living with chronic illness carry a real and persistent mental health burden, and the burden tends to surface in the same conversations where they are managing medications, asking about treatment, and looking for others who share their diagnosis.

The most common request across the dataset is the request for community.

For PLM, that is the platform’s foundational thesis turning up in every dataset.

The platform was built on the premise that finding others with your condition is therapeutic. The conversation data confirms this, with patients explicitly asking for the connection.

For Ema, the implication is a design constraint.

We need to recognise when a question about gabapentin is an entry point into a question about feeling overwhelmed.

The route to peer recognition has to be as accessible as the route to clinical information.

And a moment of disclosure, whenever it arrives, has to land somewhere it can be received and responded to with care.

For Mental Health Awareness Month, the implication for chronic illness patients is direct.

Mental health in this population does not require a separate appointment that most patients will not make. It requires the people who already share the diagnosis to be part of the conversation, and it requires the platform to make that connection fast.

That is the work. It is what the data is asking us to build.

About Morgan Rose

Morgan Rose is chief science officer at Ema, an AI platform for patient health engagement.

Ema partners with health platforms and life sciences organisations to deliver clinically grounded, emotionally intelligent AI support where patients already are.

Learn more about Ema at emahealth.ai

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.